EUVIMEDEUVIMED entdecken
Crossref

Optimizing the doses of cancer drugs after usual dose finding

Garth W Strohbehn iD, Walter M Stadler, Philip S Boonstra iD, Mark J Ratain

Clinical Trials · 2024

DOI: 10.1177/17407745231213882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Trials, 2024. Verfasst von Garth W Strohbehn und 3 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Maximum Tolerated Dose, Research Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the middle of the 20th century, oncology’s dose-finding paradigm has been oriented toward identifying a drug’s maximum tolerated dose, which is then carried forward into phase 2 and 3 trials and clinical practice. For most modern precision medicines, however, maximum tolerated dose is far greater than the minimum dose needed to achieve maximal benefit, leading to unnecessary side effects. Regulatory change may decrease maximum tolerated dose’s predominance by enforcing dose optimization of new drugs. Dozens of already approved cancer drugs require re-evaluation, however, introducing a new methodologic and ethical challenge in cancer clinical trials. In this article, we assess the history and current landscape of cancer drug dose finding. We provide a set of strategic priorities for postapproval dose optimization trials of the future. We discuss ethical considerations for postapproval dose optimization trial design and review three major design strategies for these unique trials that would both adhere to ethical standards and benefit patients and funders. We close with a discussion of financial and reporting considerations in the realm of dose optimization. Taken together, we provide a comprehensive, bird’s eye view of the postapproval dose optimization trial landscape and offer our thoughts on the next steps required of methodologies and regulatory and funding regimes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsMaximum Tolerated DoseResearch DesignDose-Response Relationship, DrugHumansClinical Trials as Topic

Stichwörter der Autor:innen

Oncologybiostatisticsclinical trial designdrug developmenthealth economicspharmacology

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA.
  • Division of Medical Oncology, Lieutenant Colonel Charles S. Kettles VA Medical Center, Ann Arbor, MI, USA.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
  • Institute for Health Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.
  • Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
  • Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

ORCID-Profile: Garth W Strohbehn, Philip S Boonstra

Zitieren

APA

Strohbehn, G. W., Stadler, W. M., Boonstra, P. S., & Ratain, M. J. (2024). Optimizing the doses of cancer drugs after usual dose finding. Clinical Trials. https://doi.org/10.1177/17407745231213882

Vancouver

Strohbehn GW, Stadler WM, Boonstra PS, Ratain MJ. Optimizing the doses of cancer drugs after usual dose finding. Clinical Trials. 2024. doi:10.1177/17407745231213882

BibTeX
@article{Strohbehn2024,
  author = {Strohbehn, Garth W and Stadler, Walter M and Boonstra, Philip S and Ratain, Mark J},
  title = {Optimizing the doses of cancer drugs after usual dose finding},
  journal = {Clinical Trials},
  year = {2024},
  doi = {10.1177/17407745231213882}
}
Kostenlos starten →